Find Oncology Drugs in Phase I Clinical Development in FRANCE

Lead Product(s): UCART19

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Servier

Deal Size: $437.6 million Upfront Cash: $27.6 million

Deal Type: Agreement February 18, 2020

Details:

Cellectis shall grant to Servier, an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products, including rights to ALLO-501A.

Lead Product(s): Hafnium dioxide

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

The U.S. FDA concluded that investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, meets the criteria for a Fast Track development program.

Lead Product(s): UCART123

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 15, 2020

Details:

AMELI-01 clinical trial uses new UCART123 construct with optimized production process & new IND number.

Lead Product(s): INVAC-1

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

This is the first in-human study of INVAC-1, an immune-therapeutic DNA vaccine for the treatment of cancer.